ProfileGDS5678 / 1428371_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 12% 13% 11% 13% 14% 11% 30% 13% 13% 13% 12% 13% 13% 12% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.3125312
GSM967853U87-EV human glioblastoma xenograft - Control 22.3151913
GSM967854U87-EV human glioblastoma xenograft - Control 32.2813411
GSM967855U87-EV human glioblastoma xenograft - Control 42.2821913
GSM967856U87-EV human glioblastoma xenograft - Control 52.2946414
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.3282511
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.7321230
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.297213
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.2985713
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.3044113
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.2993212
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.3013713
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.3115913
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.3036612